The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications it ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

in lung function improvement with an acceptable safety profile in patients with cystic fibrosis. Researchers conducted two randomized, double-blind phase 3 trials (SKYLINE VX20-121-102 and VX20 ...

These changes lead to frequent inflammation and are not affected by drugs targeting the altered mucus production. Despite new medication, cystic fibrosis often leads to permanent lung damage.

Sionna Therapeutics is working on therapies for cystic fibrosis, several of which are ... could restore function better than Vertex’s medicines. It also acquired a trio of prospects from AbbVie for ...

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...